Effects of diacerein at the molecular level in the osteoarthritis disease process

Therapeutic Advances in Musculoskeletal Disease

Volumn 2, Issue 2, 2010, Pages 95-104

  Martel Pelletier, Johanne ^a   Pelletier, Jean Pierre ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

cartilage; diacerein; osteoarthritis; rhein; subchondral bone; synovial membrane

Indexed keywords

EID: 84993683632     PISSN: 1759720X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1759720X09359104     Document Type: Review

References (68)

1. Alvarez-Soria, M.A., Herrero-Beaumont, G., Sanchez-Pernaute, O., Bellido, M. and Largo, R. ( 2008) Diacerein has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblast-comparison to its effects on osteoarthritic chondrocytes. Rheumatology (Oxford) 47: 627-633.
2. Berthiaume, M.J., Raynauld, J.P., Martel-Pelletier, J., Labonté, F., Beaudoin, G., Bloch, D.A. et al. (2005) Meniscal tear and extrusion are strongly associated with the progression of knee osteoarthritis as assessed by quantitative magnetic resonance imaging. Ann Rheum Dis 64: 556-563.
3. Blanco, F.J., Guitian, R., Vazquez-Martul, E., de Toro, F.J. and Galdo, F. (1998) Osteoarthritis chondrocytes die by apoptosis. A possible pathway for osteoarthritis pathology. Arthritis Rheum 41: 284-289.
4. Boileau, C., Tat, S.K., Pelletier, J.P., Cheng, S. and Martel-Pelletier, J. ( 2008) Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Res Ther 10: R71.
5. Bordji, K., Grillasca, J.P., Gouze, J.N., Magdalou, J., Schohn, H., Keller, J.M. et al. (2000) Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin-1beta on rat chondrocytes. J Biol Chem 275: 12243-12250.
6. Brandt, K.D. ( 2006) Studies in animal models of osteoarthritis as predictors of a structure-modifying effect of diacerhein in humans with osteoarthritis. Biorheology 43: 589-594.
7. Brandt, K.D., Smith, G., Kang, S.Y., Myers, S., O'Connor, B. and Albrecht, M. ( 1997) Effects of diacerhein in an accelerated canine model of osteoarthritis. Osteoarthritis Cartilage 5: 438-449.
8. Colville-Nash, P.R. ( 2002) Comparison of the pharmacologic effect of diacerein and a selective COX-2 inhibitor in the mouse induced-granuloma model. Presse Med 31: 4S16-4S17 (abstract).
9. Couchourel, D., Aubry, I., Delalandre, A., Lavigne, M., Martel-Pelletier, J., Pelletier, J.-P. et al. (2009) Altered mineralization of human osteoarthritic osteoblasts is due to abnormal collagen type 1 production. Arthritis Rheum 60: 1438-1450.
10. Domagala, F., Martin, G., Bogdanowicz, P., Ficheux, H. and Pujol, J.P. ( 2006) Inhibition of interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1: potential mechanism for Diacerein effects in osteoarthritis. Biorheology 43: 577-587.
11. Dougados, M., Nguyen, M., Berdah, L., Mazieres, B., Vignon, E. and Lequesne, M. ( 2001) Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum 44: 2539-2547.
12. Fahmi, H., Di Battista, J.A., Pelletier, J.P., Mineau, F., Ranger, P. and Martel-Pelletier, J. ( 2001) Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum 44: 595-607.
13. Fahmi, H., Pelletier, J.P. and Martel-Pelletier, J. ( 2002a) PPARgamma ligands as modulators of inflammatory and catabolic responses on arthritis. An overview. J Rheumatol 29: 3-14.
14. Fahmi, H., Pelletier, J.P., Mineau, F. and Martel-Pelletier, J. ( 2002b) 15d-PGJ (2) is acting as a ‘dual agent’ on the regulation of COX-2 expression in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 10: 845-848.
15. Fahmi, H., Pelletier, J.P., Di Battista, J.A., Cheung, H.S., Fernandes, J. and Martel-Pelletier, J. ( 2002c) Peroxisome proliferator-activated receptor gamma acitvators inhibit MMP-1 production in human synovial fibroblasts by reducing the activity of the activator protein 1. Osteoarthritis Cartilage 10: 100-108.
16. Fedeli, S. ( 1988) Livelli plasmatici di Diacerina nell'huomo anziano dopo somministrazioni repetute del farmaco a posologie diverse. Laboratoires NEGMA-PROTER. Study report, July 1988.
17. Felisaz, N., Boumediene, K., Ghayor, C., Herrouin, J.F., Bogdanowicz, P., Galerra, P. et al. (1999) Stimulating effect of diacerein on TGF-beta1 and beta 2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthritis Cartilage 7: 255-264.
18. Fidelix, T.S., Soares, B.G. and Trevisani, V.F. ( 2006) Diacerein for osteoarthritis. Cochrane Database Syst Rev CD005117.
19. Ghosh, P., Xu, A., Hwa, S.Y., Burkhardt, D. and Little, C. ( 1998) Evaluation of the effects of diacerhein in the sheep model of arthritis. Rev Prat 48: S24-S30.
20. Glasson, S.S., Askew, R., Sheppard, B., Carito, B., Blanchet, T., Ma, H.L. et al. (2005) Deletion of active ADAMTS 5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434: 644-648.
21. Hilal, G., Martel-Pelletier, J., Pelletier, J.P., Ranger, P. and Lajeunesse, D. ( 1998) Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: possible role in subchondral bone sclerosis. Arthritis Rheum 41: 891-899.
22. Hilal, G., Martel-Pelletier, J., Pelletier, J.P., Duval, N. and Lajeunesse, D. ( 1999) Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts. Arthritis Rheum 42: 2112-2122.
23. Hwa, S.Y., Burkhardt, D., Little, C. and Ghosh, P. ( 2001) The effects of orally administered diacerein on cartilage and subchondral bone in an ovine model of osteoarthritis. J Rheumatol 28: 825-834.
24. Ji, J.D., Cheon, H., Jun, J.B., Choi, S.J., Kim, Y.R., Lee, Y.H. et al. (2001) Effects of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) on the expression of inflammatory cytokines and apoptosis induction in rheumatoid synovial fibroblasts and monocytes. J Autoimmun 17: 215-221.
25. Kobayashi, T., Notoya, K., Naito, T., Unno, S., Nakamura, A., Martel-Pelletier, J. et al. (2005) Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. Arthritis Rheum 52: 479-487.
26. Kwan Tat, S., Pelletier, J.P., Lajeunesse, D., Fahmi, H., Lavigne, M. and Martel-Pelletier, J. ( 2008) The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol 26: 295-304.
27. Legendre, F., Bogdanowicz, P., Martin, G., Domagala, F., Leclercq, S., Pujol, J.P. et al. (2007) Rhein, a diacerhein-derived metabolite, modulates the expression of matrix degrading enzymes and the cell proliferation of articular chondrocytes by inhibiting ERK and JNK-AP-1 dependent pathways. Clin Exp Rheumatol 25: 546-555.
28. Legendre, F., Heuze, A., Boukerrouche, K., Leclercq, S., Boumediene, K., Galera, P. et al. (2009) Rhein, the metabolite of diacerhein, reduces the proliferation of osteoarthritic chondrocytes and synoviocytes without inducing apoptosis. Scand J Rheumatol 38: 104-111.
29. Martel-Pelletier, J., McCollum, R., Di Battista, J.A., Faure, M.P., Chin, J.A., Fournier, S. et al. (1992) The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis Rheum 35: 530-540.
30. Martel-Pelletier, J., Mineau, F., Jolicoeur, F.C., Cloutier, J.M. and Pelletier, J.P. ( 1998) In vitro effects of diacerhein and rhein on IL-1 and TNF-alpha systems in human osteoarthritic tissues. J Rheumatol 25: 753-762.
31. Martel-Pelletier, J., Lajeunesse, D. and Pelletier, J.P. ( 2005) Etiopathogenesis of osteoarthritis, In: Koopman, W.J. and Moreland, L.W. (eds), Arthritis & allied conditions. A textbook of rheumatology, Lippincott, Williams & Wilkins: Baltimore, pp. 2199-2226.
32. Martel-Pelletier, J., Lajeunesse, D., Reboul, P. and Pelletier, J.P. ( 2007) The role of subchondral bone in osteoarthritis, In: Sharma, L. and Berenbaum, F. (eds), Osteoarthritis: a companion to rheumatology, Mosby Elsevier: Philadelphia, pp. 15-32.
33. Martin, G., Bogdanowicz, P., Domagala, F., Ficheux, H. and Pujol, J.P. ( 2003) Rhein inhibits interleukin-1 beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappa B and AP-1 in chondrocytes cultured in hypoxia: a potential mechanism for its disease-modifying effect in osteoarthritis. Inflammation 27: 233-246.
34. Massicotte, F., Lajeunesse, D., Benderdour, M., Pelletier, J.-P., Hilal, G., Duval, N. et al. (2002) Can altered production of interleukin 1β, interleukin-6, transforming growth factor-β and prostaglandin E 2 by isolated human subchondral osteoblasts identify two subgroups of osteoarthritic patients. Osteoarthritis Cartilage 10: 491-500.
35. Mazieres, B., Berdah, L., Thiechart, M. and Viguier, G. ( 1993) Diacetylrhein on a postcontusion model of experimental osteoarthritis in the rabbit. Rev Rhum Ed Fr 60: 77S-81S.
36. Mazieres, B., Blanckaert, A., Thiechart, M. and Viguier, G. ( 1996) Diacetylrhein administrated ‘curatively’ in an experimental model of post-contusion osteoarthritis in rabbits. Rev Prat 46: S42-S45 (abstract).
37. McCollum, R., Martel-Pelletier, J., Di Battista, J.A. and Pelletier, J.P. ( 1991) Regulation of interleukin 1 receptors in human articular chondrocytes. J Rheumatol 18: 85-88.
38. Moldovan, F., Pelletier, J.P., Jolicoeur, F.C., Cloutier, J.M. and Martel-Pelletier, J. ( 2000) Diacerhein and rhein reduce the ICE-induced IL-1beta and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis Cartilage 8: 186-196.
39. Moore, A.R., Greenslade, K.J., Alam, C.A. and Willoughby, D.A. ( 1997) Effects of diacerhein on cytokine determinations in a model of cartilage degradation induced by granuloma in mice. Rev Prat 47: S24-S26 (abstract).
40. Moore, A.R., Greenslade, K.J., Alam, C.A. and Willoughby, D.A. ( 1998) Effects of diacerhein on granuloma induced cartilage breakdown in the mouse. Osteoarthritis Cartilage 6: 19-23.
41. Nicolas, P., Tod, M., Padoin, C. and Petitjean, O. ( 1998) Clinical pharmacokinetics of diacerein. Clin Pharmacokinet 35: 347-359.
42. Petitjean, O., Tod, M. and Louchahi, K. ( 1991) Étude de la pharmacocinétique de l'ART 50® en administration aigüe orale a la dose de 50 mg chez le volontaire sain âgé de 61-70 ans et de plus de 70 ans, et en administration réitérée a la dose de 50 mg x 2/jour chez le volontaire âgé de plus de 70 ans. Latoratoires NEGMA, Study PC/ART 9013N. Study report, April 1991.
43. Pelletier, J.P., Mineau, F., Fernandes, J.C., Duval, N. and Martel-Pelletier, J. ( 1998) Diacerhein and rhein reduce the interleukin 1 beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol 25: 2417-2424.
44. Pelletier, J.P., Lajeunesse, D., Reboul, P., Mineau, F., Fernandes, J.C., Sabouret, P. et al. (2001) Diacerein reduces the excess synthesis of bone remodeling factors by human osteoblast cells from osteoarthritic subchondral bone. J Rheumatol 28: 814-824.
45. Pelletier, J.P., Mineau, F., Boileau, C. and Martel-Pelletier, J. ( 2003) Diacerein reduces the level of cartilage chondrocyte DNA fragmentation and death in experimental dog osteoarthritic cartilage at the same time that it inhibits caspase-3 and inducible nitric oxide synthase. Clin Exp Rheumatol 21: 171-177.
46. Pelletier, J.P., Raynauld, J.P., Berthiaume, M.J., Abram, F., Choquette, D., Haraoui, B. et al. (2007) Risk factors associated with the loss of cartilage volume on weight bearing areas in knee osteoarthritis patients assessed by quantitative MRI: a longitudinal study. Arthritis Res Ther 9: R74.
47. Pelletier, J.-P., Raynauld, J.-P., Abram, F., Haraoui, B., Choquette, D. and Martel-Pelletier, J. ( 2008) A new non-invasive method to assess synovitis severity in relation to symptoms and cartilage volume loss in knee osteoarthritis patients using MRI. Osteoarthritis Cartilage 16: S8-S13.
48. Pomarelli, P., Berti, M., Gatti, M.T. and Mosconi, P. ( 1980) A non-steroidal anti-inflammatory drug that stimulates prostaglandin release. Farmaco 35: 836-842.
49. Pujol, J.P., Felisaz, N., Boumediene, K., Ghayor, C., Herrouin, J.F., Bogdanowicz, P. et al. (2000) Effects of diacerein on biosynthesis activities of chondrocytes in culture. Biorheology 37: 177-184.
50. Raynauld, J.P., Kauffmann, C., Beaudoin, G., Berthiaume, M.J., de Guise, J.A., Bloch, D.A. et al. (2003) Reliability of a quantification imaging system using magnetic resonance images to measure cartilage thickness and volume in human normal and osteoarthritic knees. Osteoarthritis Cartilage 11: 351-360.
51. Raynauld, J.-P., Martel-Pelletier, J., Abram, J. and Pelletier, J.-P. ( 2008a) Use of quantitative magnetic resonance imaging (qMRI) in the cross-sectional and longitudinal evaluation of structural changes in knee osteoarthritis (OA) patients, In: Reid, D.M., Miller, C.G. and Baburaj, K. (eds), Clinical trials in rheumatoid arthritis and osteoarthritis, Springer-Verlag: London.
52. Raynauld, J.-P., Martel-Pelletier, J., Berthiaume, M.-J., Abram, F., Choquette, D., Haraoui, B. et al. (2008 b) Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period. Ann Rheum Dis 67: 683-688.
53. Raynauld, J.P., Martel-Pelletier, J., Berthiaume, M.J., Beaudoin, G., Choquette, D., Haraoui, B. et al. (2006) Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther 8: R21.
54. Raynauld, J.P., Martel-Pelletier, J., Berthiaume, M.J., Labonté, F., Beaudoin, G., de Guise, J.A. et al. (2004) Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis Rheum 50: 476-487.
55. Redini, F., Galera, P., Mauviel, A., Loyau, G. and Pujol, J.P. ( 1988) Transforming growth factor beta stimulates collagen and glycosaminoglycan biosynthesis in cultured rabbit articular chondrocytes. FEBS Lett 234: 172-176.
56. Rintelen, B., Neumann, K. and Leeb, B.F. ( 2006) A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med 166: 1899-1906.
57. Sadouk, M., Pelletier, J.P., Tardif, G., Kiansa, K., Cloutier, J.M. and Martel-Pelletier, J. ( 1995) Human synovial fibroblasts coexpress interleukin-1 receptor type I and type II mRNA: the increased level of the interleukin-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor. Lab Invest 73: 347-355.
58. Saha, N., Moldovan, F., Tardif, G., Pelletier, J.P., Cloutier, J.M. and Martel-Pelletier, J. ( 1999) Interleukin-1beta-converting enzyme/Caspase-1 in human osteoarthritic tissues: localization and role in the maturation of IL-1beta and IL-18. Arthritis Rheum 42: 1577-1587.
59. Sanchez, C., Mathy-Hartert, M., Deberg, M.A., Ficheux, H., Reginster, J.Y. and Henrotin, Y.E. ( 2003) Effects of rhein on human articular chondrocytes in alginate beads. Biochem Pharmacol 65: 377-388.
60. Segré, G. ( 1988) Étude pilote du passage de la rhéine dans le liquide synovial. Laboratoires NEGMA, Study 4A29. Study report, July 1988.
61. Simonin, M.A., Bordji, K., Boyault, S., Bianchi, A., Gouze, E., Becuwe, P. et al. (2002) PPAR-gamma ligands modulate effects of LPS in stimulated rat synovial fibroblasts. Am J Physiol Cell Physiol 282: C125-C133.
62. Smith Jr, G.N., Myers, S.L., Brandt, K.D., Mickler, E.A. and Albrecht, M. ( 1999) Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis. Arthritis Rheum 42: 545-554.
63. Sokoloff, L. ( 1993) Microcracks in the calcified layer of articular cartilage. Arch Pathol Lab Med 117: 191-195.
64. Spencer, C.M. and Wilde, M.I. ( 1997) Diacerein. Drugs 53: 98-108.
65. Stanton, H., Rogerson, F.M., East, C.J., Golub, S.B., Lawlor, K.E., Meeker, C.T. et al. (2005) ADAMTS 5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434: 648-652.
66. Tamura, T. and Ohmori, K. ( 2001) Rhein, an active metabolite of diacerein, suppresses the interleukin-1alpha-induced proteoglycan degradation in cultured rabbit articular chondrocytes. Jpn J Pharmacol 85: 101-104.
67. Tamura, T., Shirai, T., Kosaka, N., Ohmori, K. and Takafumi, N. ( 2002) Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. Eur J Pharmacol 448: 81-87.
68. Yaron, M., Shirazi, I. and Yaron, I. ( 1999) Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis Cartilage 7: 272-280.